ONO-4538
Phase 3Small molecule
Ono Pharmaceutical Co. LtdONO-4538 is one of 226 small molecule programs targeting Phase II. It is currently in Phase 3.
8
Indications
20
Total Trials
10
Active Trials
225
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Retevmo
Eli LillyPhase 3
Tepmetko
EMD SeronoPhase 3
ONO-4538
Ono Pharmaceutical Co. LtdPhase 3
Taletrectinib
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer4 trials
Pancreatic Cancer3 trials
Gastric Cancer3 trials
Colorectal Cancer2 trials
6 more indications
Patients With Solid Tumors1 trial
Advanced Malignant Solid Tumors1 trial
Advanced or Metastatic Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ONO-4538. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company